HRMY, US4131971040

Harmony Biosciences names Anastasiou CEO: Ladenburg targets Harmony Biosciences stock at USD 55.00

Published on 10/16/2026 at 03:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

WAKIX revenue hit USD 261.28 million in the second quarter, up 30.30 percent year over year. Harmony Biosciences stock has USD 1.00 billion guidance.

Leadership transition and growth figures

Peter Anastasiou becomes chief executive on January 1, 2027.
Second-quarter revenue reached USD 261.28 million, up 30.30 percent year over year.
Harmony Biosciences carried a USD 2.2 billion market capitalization as of October 15, 2026.

HRMY, US4131971040, Illustration mit AI erstellt.

Harmony Biosciences (ISIN US4131971040) appointed Peter Anastasiou as its next chief executive on October 12, 2026, while reiterating full-year 2026 WAKIX net revenue guidance of USD 1.00 billion to USD 1.04 billion, according to GlobeNewswire. The leadership change keeps attention on execution across WAKIX and the central nervous system pipeline.

Three dated milestones and figures

On August 4, 2026, Harmony reported second-quarter revenue of USD 261.28 million, with net income of USD 75.43 million, according to Simply Wall St. On October 1, 2026, the company outlined two ongoing Phase 3 trials for HBS-301 and multiple tablet strengths up to 60 milligrams at the European Narcolepsy Days, as reported by GlobeNewswire. On October 12, 2026, Harmony named Anastasiou as CEO from January 1, 2027, and retained the USD 1.00 billion to USD 1.04 billion WAKIX outlook.

What does the transition mean?

The immediate financial anchor is the WAKIX range of USD 1.00 billion to USD 1.04 billion for 2026. Second-quarter revenue of USD 261.28 million was 30.30 percent higher than in the same period of 2025, while net income rose to USD 75.43 million from USD 39.78 million, according to Simply Wall St. The figures give Anastasiou a commercial base as he takes over from Jeffrey M. Dayno.

Upcoming dates and pipeline milestones

Anastasiou is scheduled to become president and CEO on January 1, 2027, while Dayno is scheduled to retire on December 31, 2026. Harmony also said on October 12, 2026, that data from the BP-205 multiple ascending dose study remained on track for the fourth quarter of 2026, according to GlobeNewswire.

Market value and investor context

Harmony describes itself as a commercial-stage pharmaceutical company focused on rare neurological disorders, with WAKIX as its principal commercial product. The October 15, 2026 market snapshot placed the company at a USD 2.2 billion market capitalization, leaving the leadership handover and pipeline delivery as the central markers for the next phase.